Currently Enrolling Studies
Below is a list of our currently enrolling studies. These are always changing so be sure to come back and check for new studies. Scroll below the "featured study" to find the other enrolling studies.
Please do not hesitate to contact us with any questions at (509) 623-9768.
Full List of Studies:
o Study GR40548 is a Phase III, randomized, multicenter, open-label (visual assessor [VA]-masked), active-comparator study designed to assess the efficacy, safety, and pharmacokinetics (PK) of 100mg/ml delivered via the Port Delivery System (PDS) compared with ranibizumab intravitreal injections at 0.5 mg (10 mg/mL) in participants with neovascular age-related macular degeneration (nAMD).
Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular Age-related Wet Macular Degeneration (PANDA-1)
The purpose of this clinical study is to evaluate the efficacy and safety of two different levels of conbercept intravitreal (IVT) injection as compared to the approved vascular endothelial growth factor (VEGF) antagonist active control, aflibercept intravitreal injection (2.0 mg/eye, Eylea®), in subjects with neovascular AMD.
Do you have age-related macular degeneration (AMD)? Consider participating in the SCOPE study to help advanceAMD research! The SCOPE study is a Natural History research study that will gather information on your disease and how it develops over time. You will not receive any treatment as a study participant. The first step is providing a saliva sample in a tube to see if you qualify. Click the photo below to take the first step!
This is a 30-month, Phase III, multi-center, randomized, double-masked, sham-injection controlled study to assess the efficacy and safety of multiple IVT injections of APL-2 in subjects with GA secondary to AMD.
A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)
This study will evaluate the efficacy, safety, and pharmacokinetics of faricimab administered at 8-week intervals or as specified in the protocol following treatment initiation, compared with aflibercept once every 8 weeks (Q8W), in participants with diabetic macular edema (DME).
Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema (KESTREL)
The purpose of this study is to evaluate the efficacy and safety of brolucizumab in treatment of patients with visual impairment due to diabetic macular edema (DME).
Myopia means your child has trouble seeing things clearly in the distance, but can see things well up close because the eye is too long. Identifying a way to control myopia progression is a key step towards preserving eyesight and preventing serious eye disease. The CHAMP research study is currently enrolling children ages 3 to 10 to evaluate an investigational eye drop being evaluated to slow the progression of nearsightedness (myopia) in children. About 500 children will take part in this study. To pre‐qualify for this study, your child must be 3 to 10 years of age and must have been diagnosed with nearsightedness (myopia)
Compare the efficacy of 1 hour/day of binocular game play 5 days per week plus spectacle correction with spectacle correction only, for treatment of amblyopia in children 4 to <13 years of age.
This is an observational, multicenter study to determine the prevalence of Cerebrotendinous Xanthomatosis (CTX) in patient populations diagnosed with early-onset idiopathic bilateral cataracts. Patients who are potentially eligible for study participation will be identified through a chart review of patients who were seen at each study site prior to that site's initiation, or by entering care at the site while the site is participating in the trial.